Table 1.
Demographic features and general characteristics of patients*.
| Feature | Data |
|---|---|
| Age at initiation of IFN-α2a, mean±SD, years | 30.5 ± 8.7 |
| Total follow-up, mean±SD, months | 21.7 ± 7.5 |
| Gender ratio (M/F) | 27/3 |
| Ocular manifestations | |
| Affected sites | |
| Bilateral | 28 (93.3) |
| Panuveitis | 30 (100) |
| Retinal vasculitis | 7 (23.3) |
| Macular edema | 5 (16.7) |
| Cataract | 9 (30) |
| Extraocular manifestations | |
| Recurrent oral ulcers | 30 (100) |
| Genital ulcers | 18 (60) |
| Arthritis | 1 (3.3) |
| Skin lesions | 22 (73.3) |
| Pathergy test positive | 4 (13.3) |
| Epididymitis | 1 (3.3) |
| Concomitant diseases | |
| Chronic hepatitis B virus infection | 2 (6.7) |
| Pulmonary tuberculosis | 1 (3.3) |
| Ankylosing spondylitis | 1 (3.3) |
| Previous therapy | |
| Glucocorticoids | 30 (100) |
| Minimum maintenance dosage, median (range), mg/day |
20 (15–60) |
| Immunosuppressants | 30 (100) |
| Combination therapy | 21 (70) |
| Biological agents (short terms)# | 4 (13.3) |
| Adverse events of previous therapy | |
| Avascular necrosis | 2 (6.7) |
| Secondary hypertension | 4 (13.3) |
| Liver function impairment | 5 (16.7) |
| Renal function impairment | 3 (10) |
| Cyclophosphamide-induced hematuria | 2 (6.7) |
*
Unless otherwise indicated, data are expressed as number (percentage) of patients.
#
Etanercept in four cases (13.3%) and infliximab in two cases (6.7%).